JAK-3 SCID gene therapy

N/A

Report date: 2022/03/22 09:42:14

Base Information

Drug NameJAK-3 SCID gene therapy
Drug Alias NameSCID JAK-3 gene therapyJAK-3严重联合免疫缺陷病（SCID）基因疗法SCID gene therapy
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionGene transferenceLymphocytes stimulantsTyrosine-protein kinase JAK3 inhibitors
TargetsTyrosine-protein kinase JAK3
Therapy Area/IndicationsImmune System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive Companies +[1]  N/A
Active IndicationsN/A
Inactive IndicationsImmune System Diseases

Other Information

ATC CodeN/A
Related LinksN/A